Seagen Deal Ticks The Big Three For Pfizer: Revenues, Pipeline, Platform

Pfizer expects Seagen’s portfolio of approved drugs and development pipeline to add $10bn in annual revenue by 2030.  

A Pfizer building sign in midtown Manhattan
• Source: Shutterstock

Pfizer Inc. agreed to pay $43bn in cash for antibody-drug conjugate (ADC) developer Seagen Inc. earlier this month. The US pharma giant said Seagen’s four approved products – three ADCs and a small molecule cancer drug – plus candidates in its pipeline should generate $10bn in annual revenue by 2030. This puts Pfizer less than $5bn away from achieving its goal of adding $25bn in new revenue by 2030 through business development activities.

That level of investment is needed to offset losses of exclusivity (LOEs) later in this decade for multiple blockbuster products, including the CDK4/6 inhibitor Ibrance (palbociclib) for breast cancer

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By 

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

Laying The Foundation And Overcoming Prerequisites To Establish AI Within Health Care

 
• By 

As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.

Aurion Biotech’s Ophthalmic Cell Therapy For The Masses

 
• By 

Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.

Neurodegenerative Disease Investment: Shifting Paradigms Beyond Amyloid And Tau

 
• By 

Companies are exploring new mechanisms of action beyond traditional amyloid and tau and both investors and big pharma are willing to make deals when the science is compelling, panelists at Biotech Showcase said.

More from In Vivo

Digital Transformation At The FDA: Generative AI Set To Transform Drug Review Process

 
• By 

The FDA plans to implement generative AI for drug reviews by 30 June 2025, enhancing efficiency and potentially accelerating approval processes. Discussions with OpenAI about AI integration are ongoing.

Deals Shaping The Industry, April 2025

 
• By 

An interactive look at pharma, medtech and diagnostics deals made during April 2025. Data courtesy of Biomedtracker.

Plans For London Cancer Hub Promises New Destination For Biotech Innovation

 
• By 

Plans have been submitted for a £1bn development in London that can home biotech companies and encourages cross collaboration with the Institute of Cancer Research. In Vivo took an exclusive tour of the UK’s prospective new cancer innovation district.